The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

Clicks: 384
ID: 114929
2004
Daptomycin is the first available agent from a new class of antibiotics, the cyclic lipopeptides, that has activity against a broad range of gram-positive pathogens, including organisms that are resistant to methicillin, vancomycin, and other currently available agents. Daptomycin (4 mg/kg intraveno …
Reference Key
rd2004clinicalthe Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Arbeit RD;Maki D;Tally FP;Campanaro E;Eisenstein BI; ;;
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2004
DOI DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/15227611
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome adult female male aged middle aged Skin Diseases Comparative Study Clinical Trial Phase III Randomized Controlled Trial Multicenter Study anti-bacterial agents / adverse effects penicillins / therapeutic use anti-bacterial agents / administration & dosage anti-bacterial agents / therapeutic use* vancomycin / therapeutic use intravenous soft tissue infections / drug therapy* infectious / drug therapy* infusions pmid:15227611 doi:10.1086/420818 robert d arbeit dennis maki daptomycin 98-01 and 99-01 investigators daptomycin / administration & dosage daptomycin / adverse effects daptomycin / therapeutic use*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.